Compounded Peptide Products Marketed as Wellness Therapies
The growing popularity of “wellness peptides” has outpaced the clinical evidence needed to support their safety and effectiveness. Marketed for benefits such as muscle growth, anti-aging, and recovery, many of these products remain unapproved for human use and are widely available through unregulated channels.
In this white paper, ECRI and the Institute for Safe Medication Practices examine the risks associated with these products, including gaps in clinical evidence, quality concerns, and emerging safety signals. The report also explores recent policy changes from the U.S. Food and Drug Administration and what they mean for patient safety.
Learn how the rapid expansion of the peptide market is creating new risks—and what patients, clinicians, and policymakers should consider before use.